Ergosterol peroxide glucosideCAS# 140447-22-9 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 140447-22-9 | SDF | Download SDF |
| PubChem ID | 10745980 | Appearance | Powder |
| Formula | C34H54O8 | M.Wt | 590.8 |
| Type of Compound | Steroids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | (2R,3R,4S,5S,6R)-2-[[(1S,2R,5R,6R,9R,10R,13S,15S)-5-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-6,10-dimethyl-16,17-dioxapentacyclo[13.2.2.01,9.02,6.010,15]nonadec-18-en-13-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol | ||
| SMILES | CC(C)C(C)C=CC(C)C1CCC2C1(CCC3C24C=CC5(C3(CCC(C5)OC6C(C(C(C(O6)CO)O)O)O)C)OO4)C | ||
| Standard InChIKey | CKJZKFPVVUQBMB-AGBBTXFXSA-N | ||
| Standard InChI | InChI=1S/C34H54O8/c1-19(2)20(3)7-8-21(4)23-9-10-25-31(23,5)13-12-26-32(6)14-11-22(17-33(32)15-16-34(25,26)42-41-33)39-30-29(38)28(37)27(36)24(18-35)40-30/h7-8,15-16,19-30,35-38H,9-14,17-18H2,1-6H3/b8-7+/t20-,21+,22-,23+,24+,25+,26+,27+,28-,29+,30+,31+,32+,33+,34-/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | 1. Ergosterol peroxide exhibits inhibitory effects on human breast adenocarcinoma MCF-7 cells, it inhibits the growth of MCF-7 cells by inducing cell apoptosis. 2. Ergosterol peroxide exhibits hACAT-1 and Lp-PLA2 inhibitory effects, with inhibitory values of 51.6 +/- 0.9 and 51.7 +/- 1.2%, at a treatment concentration of 0.23 mM; suggests that it could as an anti-atherosclerosis agent. 3. Ergosterol peroxide shows very strong anticomplementary activity on the classical pathway, the IC(50) values being 5.0 muM. 4. Ergosterol peroxide can suppress inflammatory responses in RAW264.7 macrophages and growth of HT29 colon adenocarcinoma cells, it appears to suppress cell growth and STAT1 mediated inflammatory responses by altering the redox state in HT29 cells. 5. Ergosterol peroxide has anti-melanogenic activity. 6. Ergosterol peroxide has amoebicidal activity (IC50 =4.23nM), it produces a strong cytotoxic effect against amoebic growth. 7. Ergosterol peroxide has osteoclastogenesis inhibitory effect, it shows an inhibitory effect in a dose-dependent manner and an inhibition rate of up to 62% with low cytotoxicity, even at a concentration as low as 1.0 microg/mL. 8. Ergosterol peroxide has antibacterial activity against Mycobacterium tuberculosis and has antiviral action. 9. Ergosterol peroxide has anti-oxdiant activity. |
Ergosterol peroxide glucoside Dilution Calculator
Ergosterol peroxide glucoside Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.6926 mL | 8.4631 mL | 16.9262 mL | 33.8524 mL | 42.3155 mL |
| 5 mM | 0.3385 mL | 1.6926 mL | 3.3852 mL | 6.7705 mL | 8.4631 mL |
| 10 mM | 0.1693 mL | 0.8463 mL | 1.6926 mL | 3.3852 mL | 4.2316 mL |
| 50 mM | 0.0339 mL | 0.1693 mL | 0.3385 mL | 0.677 mL | 0.8463 mL |
| 100 mM | 0.0169 mL | 0.0846 mL | 0.1693 mL | 0.3385 mL | 0.4232 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 11-Hydroxyjasmonic acid
Catalog No.:BCN6221
CAS No.:140447-14-9
- GSK 2830371
Catalog No.:BCC4179
CAS No.:1404456-53-6
- ML 281
Catalog No.:BCC6317
CAS No.:1404437-62-2
- Fmoc-Dap(Dnp)-OH
Catalog No.:BCC2666
CAS No.:140430-54-2
- 7-Methoxycoumarin-4-acetyl-P-L-G-L-β-(2,4-dinitrophenylamino)A-R amide
Catalog No.:BCC1086
CAS No.:140430-53-1
- ON 146040
Catalog No.:BCC8058
CAS No.:1404231-34-0
- CCT244747
Catalog No.:BCC6423
CAS No.:1404095-34-6
- RSVA 405
Catalog No.:BCC8016
CAS No.:140405-36-3
- Vancomycin hydrochloride
Catalog No.:BCC4232
CAS No.:1404-93-9
- 6'-O-Cinnamoyl-8-epikingisidic acid
Catalog No.:BCN7059
CAS No.:1403984-03-1
- Nexturastat A
Catalog No.:BCC5345
CAS No.:1403783-31-2
- PFI-1 (PF-6405761)
Catalog No.:BCC2225
CAS No.:1403764-72-6
- Heteroclitin C
Catalog No.:BCN3632
CAS No.:140460-42-0
- Heteroclitin B
Catalog No.:BCN3745
CAS No.:140461-47-8
- Olopatadine HCl
Catalog No.:BCC4545
CAS No.:140462-76-6
- Neomycin sulfate
Catalog No.:BCC4682
CAS No.:1405-10-3
- Capreomycin Sulfate
Catalog No.:BCC4644
CAS No.:1405-37-4
- Gentamycin Sulfate
Catalog No.:BCC1203
CAS No.:1405-41-0
- Tylosin phosphate
Catalog No.:BCC5551
CAS No.:1405-53-4
- Glycyrrhizic acid
Catalog No.:BCN5941
CAS No.:1405-86-3
- Bacitracin
Catalog No.:BCC4632
CAS No.:1405-87-4
- Bacitracin Zinc
Catalog No.:BCC4633
CAS No.:1405-89-6
- 1,2-Methylenedioxy-3,10,11-trimethoxynoraporphine
Catalog No.:BCN1573
CAS No.:14050-90-9
- Methyl chanofruticosinate
Catalog No.:BCN6223
CAS No.:14050-92-1
Ergosterol peroxide from flowers of Erigeron annuus L. as an anti-atherosclerosis agent.[Pubmed:15974439]
Arch Pharm Res. 2005 May;28(5):541-5.
Flowers of Erigeron annuus L. were extracted with 80% aqueous MeOH, and the concentrated extract was partitioned with EtOAc, n-BuOH, and H2O. Repeated silica gel and ODS column chromatography of the EtOAc fraction led to the isolation of a sterol, through activity-guided fractionation, using ACAT inhibitory activity measurements. From the physico-chemical data, including NMR, MS, and IR, the chemical structure of the compound was determined to be an ergosterol peroxide (1), which has been isolated for the first time from this plant. This compound exhibited hACAT-1 and Lp-PLA2 inhibitory effects, with inhibitory values of 51.6 +/- 0.9 and 51.7 +/- 1.2%, at a treatment concentration of 0.23 mM.
Ergosterol peroxide from an edible mushroom suppresses inflammatory responses in RAW264.7 macrophages and growth of HT29 colon adenocarcinoma cells.[Pubmed:17160010]
Br J Pharmacol. 2007 Jan;150(2):209-19.
BACKGROUND AND PURPOSE: 5alpha,8alpha-Epidioxy-22E-ergosta-6, 22-dien-3beta-ol (ergosterol peroxide) is a major antitumour sterol produced by edible or medicinal mushrooms. However, its molecular mechanism of action has yet to be determined. Here, we examine the anticancer and anti-inflammatory effects of ergosterol peroxide. EXPERIMENTAL APPROACH: After treating RAW264.7 macrophages with LPS and purified ergosterol peroxide or ergosterol, we determined LPS-induced inflammatory cytokines, nuclear DNA binding activity of transcription factors and phosphorylation of MAP kinases (MAPKs). HT29 colorectal adenocarcinoma cells were treated with ergosterol peroxide for 5 days. To investigate the antitumour properties of ergosterol peroxide, we performed DNA microarray and RT-PCR analyses and determined the reactive oxygen species (ROS) in HT29 cells. KEY RESULTS: Ergosterol peroxide suppressed LPS-induced TNF-alpha secretion and IL-1alpha/beta expression in RAW264.7 cells. Ergosterol peroxide and ergosterol suppressed LPS-induced DNA binding activity of NF-kappaB and C/EBPbeta, and inhibited the phosphorylation of p38, JNK and ERK MAPKs. Ergosterol peroxide down-regulated the expression of low-density lipoprotein receptor (LDLR) regulated by C/EBP, and HMG-CoA reductase (HMGCR) in RAW264.7 cells. In addition, ergosterol peroxide showed cytostatic effects on HT29 cells and increased intracellular ROS. Furthermore, ergosterol peroxide induced the expression of oxidative stress-inducible genes, and the cyclin-dependent kinase inhibitor CDKN1A, and suppressed STAT1 and interferon-inducible genes. CONCLUSION AND IMPLICATION: Our results suggest that ergosterol peroxide and ergosterol suppress LPS-induced inflammatory responses through inhibition of NF-kappaB and C/EBPbeta transcriptional activity, and phosphorylation of MAPKs. Moreover, ergosterol peroxide appears to suppress cell growth and STAT1 mediated inflammatory responses by altering the redox state in HT29 cells.
